What is the recommended diagnostic and treatment approach for a patient suspected of having Hypertrophic Obstructive Cardiomyopathy (HOCM) with symptoms such as chest pain, shortness of breath, or syncope?

Diagnosis of Hypertrophic Obstructive Cardiomyopathy (HOCM)

For patients with suspected HOCM, obtain a comprehensive physical examination with provocative maneuvers, 12-lead ECG, and transthoracic echocardiography as the mandatory initial diagnostic triad. 1, 2

Initial Clinical Assessment

Perform a detailed 3-generation family pedigree to identify relatives with HCM, unexplained sudden death, heart failure, cardiac transplantation, or pacemaker/ICD implants. 1, 2

Document specific symptoms in relation to exertion:

• Chest pain (angina)
• Dyspnea (shortness of breath)
• Palpitations
• Syncope or presyncope (lightheadedness) 1, 2

Physical examination must include provocative maneuvers (Valsalva, squat-to-stand, passive leg raising, walking) to elicit left ventricular outflow tract obstruction. 2 The classic findings include a harsh crescendo-decrescendo systolic murmur that increases with Valsalva or standing, prominent apical point of maximal impulse, abnormal carotid pulse, and a fourth heart sound. 1

Screen for syndromic features including ataxia, hearing/visual impairment, cognitive abnormalities, or neurodevelopmental issues that suggest phenocopy conditions (Anderson-Fabry disease, Noonan syndrome, amyloidosis, glycogen storage diseases). 2

Mandatory Diagnostic Testing

12-Lead Electrocardiography

A 12-lead ECG is mandatory in all patients with suspected HCM, with abnormalities present in 75-95% of cases. 3, 4, 2, 5 ECG patterns may mimic myocardial infarction and can be present before wall thickening is evident on echocardiography. 4

Transthoracic Echocardiography (Primary Imaging Modality)

TTE is the cornerstone diagnostic test recommended for initial evaluation of all suspected HCM patients. 6, 1, 3, 4, 2, 5

Diagnostic criteria:

• ≥15 mm maximal wall thickness in any left ventricular segment in adults 2, 5
• ≥13 mm in first-degree relatives of patients with confirmed HCM 2, 5
• In children: LV wall thickness >2 standard deviations above predicted mean (z-score >2) 5

Essential echocardiographic measurements:

• Maximum diastolic wall thickness using 2D short-axis views in all LV segments from base to apex 2
• Left ventricular outflow tract (LVOT) gradient assessment with peak instantaneous gradients 2
• LV diastolic function including pulsed Doppler of mitral valve inflow, tissue Doppler velocities at mitral annulus, pulmonary vein flow velocities, pulmonary artery systolic pressure, and left atrial size/volume 2
• Systolic anterior motion (SAM) of the mitral valve 1
• Mitral regurgitation severity and mechanism 6, 1

Perform imaging at rest and during provocative maneuvers:

• Valsalva maneuver in sitting and semi-supine positions
• Standing position if no gradient is provoked 2

Provocative Testing for Dynamic Obstruction

For patients with resting LVOT gradient <50 mm Hg, perform TTE with provocative maneuvers. 6

For symptomatic patients without resting or provocable gradient ≥50 mm Hg on standard TTE, perform exercise TTE in standing, sitting, or semi-supine position to detect exercise-induced LVOTO and mitral regurgitation. 6, 3, 4, 2

24-Hour Ambulatory (Holter) Monitoring

Holter monitoring is recommended in the initial evaluation to detect nonsustained ventricular tachycardia (NSVT) and identify candidates for ICD therapy. 3, 5 This should also be performed in patients who develop palpitations or lightheadedness. 3

Advanced Imaging Considerations

Cardiovascular Magnetic Resonance (CMR)

CMR is indicated when echocardiography is inconclusive, particularly for:

• Suspected apical HCM or apical aneurysm 6
• Atypical patterns of hypertrophy 6
• Suboptimal echocardiographic images 2
• Suspicion of alternative diagnoses (amyloidosis, myocarditis, Anderson-Fabry disease) 7

Transesophageal Echocardiography (TEE)

Consider TEE when:

• The mechanism of LVOTO is unclear 2
• Assessing mitral valve apparatus before septal reduction procedures 2
• Severe mitral regurgitation from intrinsic valve abnormalities is suspected 2
• TTE is inconclusive for clinical decision-making 6, 3, 4

Contrast Echocardiography

Consider TTE with LV cavity opacification using intravenous contrast in patients with suboptimal images or suspected LV apical hypertrophy or aneurysm as an alternative to CMR. 6, 2

Echocardiographic Red Flags for Phenocopy Conditions

Specific features suggesting alternative diagnoses:

• Increased interatrial septum thickness: Consider amyloidosis 2
• Increased AV valve thickness: Consider amyloidosis or Anderson-Fabry disease 2
• Increased RV free wall thickness: Consider amyloidosis, myocarditis, Anderson-Fabry disease, or Noonan syndrome 2
• Mild to moderate pericardial effusion: Consider amyloidosis or myocarditis 2
• Ground-glass appearance: Consider amyloidosis 2
• Concentric LVH: Consider glycogen storage disease, Anderson-Fabry disease, or PRKAG2 mutations 2
• Extreme concentric LVH (≥30 mm): Consider Danon disease or Pompe disease 2
• Global LV hypokinesia: Consider mitochondrial disease, TTR-related amyloidosis, PRKAG2 mutations, Danon disease, myocarditis, or advanced sarcomeric HCM 2

Genetic Testing

Genetic testing is recommended in the index patient to facilitate identification of at-risk first-degree family members. 2, 7 Counseling by someone knowledgeable in cardiovascular genetics must accompany testing. 2

Family Screening Protocol

For first-degree relatives of confirmed HCM patients, clinical screening (physical exam, ECG, TTE) is mandatory unless genotype-negative in families with known definitive mutations. 3, 4, 2, 5

Screening intervals:

• Children/adolescents (ages 12-18/21 years): Every 12-18 months 6, 1, 3, 4, 2, 5
• Adults (>18/21 years): Approximately every 5 years if asymptomatic 6, 1, 2, 5
• Genotype-positive, phenotype-negative individuals: Every 12-18 months in children/adolescents, every 3-5 years in adults 6, 1

Start screening earlier (before age 12) if growth spurt or signs of puberty are evident, plans for intense competitive sports exist, or family history of sudden cardiac death is present. 3, 4

Follow-Up Imaging

For patients with HCM and no change in clinical status, repeat TTE every 1-2 years to assess degree of myocardial hypertrophy, dynamic LVOTO, mitral regurgitation, and myocardial function. 6, 1, 7

For patients with change in clinical status or new cardiovascular event, perform repeat TTE immediately. 6, 3, 4

Critical Differential Diagnoses to Exclude

Age-specific considerations:

• Neonates/infants: Inherited metabolic disorders, congenital dysmorphic syndromes, maternal gestational diabetes 1, 2
• Men >65 years: Wild-type TTR-related amyloidosis 2

Other mimics to exclude:

• Physiologic athletic remodeling 2, 8
• Long-standing systemic hypertension 1, 2
• Renal disease 1
• Infiltrative diseases (amyloidosis) 2, 8

Common Pitfalls

Do not perform TTE more frequently than every 12 months in stable patients when changes unlikely to impact clinical decision-making. 3

Do not rely solely on resting echocardiography in symptomatic patients—provocative maneuvers or exercise testing are essential to unmask dynamic obstruction. 6, 2

Do not miss phenocopy conditions—always assess for syndromic features and consider alternative diagnoses, particularly in extreme phenotypes or atypical presentations. 2